Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

The angiostatic protein 16K human prolactin significantly prevents tumor-induced lymphangiogenesis by affecting lymphatic endothelial cells.

Kinet V, Castermans K, Herkenne S, Maillard C, Blacher S, Lion M, Noël A, Martial JA, Struman I.

Endocrinology. 2011 Nov;152(11):4062-71. doi: 10.1210/en.2011-1081. Epub 2011 Aug 23.

PMID:
21862622
2.

The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation.

Tabruyn SP, Sabatel C, Nguyen NQ, Verhaeghe C, Castermans K, Malvaux L, Griffioen AW, Martial JA, Struman I.

Mol Endocrinol. 2007 Jun;21(6):1422-9. Epub 2007 Apr 3.

3.

The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation.

Nguyen NQ, Castermans K, Berndt S, Herkenne S, Tabruyn SP, Blacher S, Lion M, Noel A, Martial JA, Struman I.

PLoS One. 2011;6(11):e27318. doi: 10.1371/journal.pone.0027318. Epub 2011 Nov 7.

4.

The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis.

Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI.

Endocrinology. 1993 Sep;133(3):1292-9.

PMID:
7689950
5.

Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis.

Sabatel C, Cornet AM, Tabruyn SP, Malvaux L, Castermans K, Martial JA, Struman I.

Mol Cancer. 2010 Sep 2;9:231. doi: 10.1186/1476-4598-9-231.

6.

Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice.

Pan H, Nguyen NQ, Yoshida H, Bentzien F, Shaw LC, Rentier-Delrue F, Martial JA, Weiner R, Struman I, Grant MB.

Invest Ophthalmol Vis Sci. 2004 Jul;45(7):2413-9.

7.

Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice.

Bentzien F, Struman I, Martini JF, Martial J, Weiner R.

Cancer Res. 2001 Oct 1;61(19):7356-62.

8.

The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases.

Tabruyn SP, Nguyen NQ, Cornet AM, Martial JA, Struman I.

Mol Endocrinol. 2005 Jul;19(7):1932-42. Epub 2005 Mar 3.

9.

The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation.

Martini JF, Piot C, Humeau LM, Struman I, Martial JA, Weiner RI.

Mol Endocrinol. 2000 Oct;14(10):1536-49.

10.

Role of CD11b+ macrophages in intraperitoneal lipopolysaccharide-induced aberrant lymphangiogenesis and lymphatic function in the diaphragm.

Kim KE, Koh YJ, Jeon BH, Jang C, Han J, Kataru RP, Schwendener RA, Kim JM, Koh GY.

Am J Pathol. 2009 Oct;175(4):1733-45. doi: 10.2353/ajpath.2009.090133. Epub 2009 Sep 17.

11.

Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth.

Kinet V, Nguyen NQ, Sabatel C, Blacher S, Noël A, Martial JA, Struman I.

Cancer Lett. 2009 Nov 1;284(2):222-8. doi: 10.1016/j.canlet.2009.04.030. Epub 2009 May 26.

13.

16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells.

D'Angelo G, Martini JF, Iiri T, Fantl WJ, Martial J, Weiner RI.

Mol Endocrinol. 1999 May;13(5):692-704.

PMID:
10319320
14.

Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance.

Piwnica D, Touraine P, Struman I, Tabruyn S, Bolbach G, Clapp C, Martial JA, Kelly PA, Goffin V.

Mol Endocrinol. 2004 Oct;18(10):2522-42. Epub 2004 Jun 10.

15.

Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer.

Jia Y, Liu M, Huang W, Wang Z, He Y, Wu J, Ren S, Ju Y, Geng R, Li Z.

Pathol Oncol Res. 2012 Apr;18(2):315-23. doi: 10.1007/s12253-011-9447-y. Epub 2011 Sep 22.

16.

Delphinidin is a novel inhibitor of lymphangiogenesis but promotes mammary tumor growth and metastasis formation in syngeneic experimental rats.

Thiele W, Rothley M, Teller N, Jung N, Bulat B, Plaumann D, Vanderheiden S, Schmaus A, Cremers N, Göppert B, Dimmler A, Eschbach V, Quagliata L, Thaler S, Marko D, Bräse S, Sleeman JP.

Carcinogenesis. 2013 Dec;34(12):2804-13. doi: 10.1093/carcin/bgt291. Epub 2013 Aug 23.

PMID:
23975834
17.

Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL.

Nguyen NQ, Cornet A, Blacher S, Tabruyn SP, Foidart JM, Noël A, Martial JA, Struman I.

Mol Ther. 2007 Dec;15(12):2094-100. Epub 2007 Aug 28.

18.

Endostatin inhibits tumour lymphangiogenesis and lymphatic metastasis via cell surface nucleolin on lymphangiogenic endothelial cells.

Zhuo W, Luo C, Wang X, Song X, Fu Y, Luo Y.

J Pathol. 2010 Nov;222(3):249-60. doi: 10.1002/path.2760.

PMID:
20814900
19.

Molecular control of lymphatic metastasis.

Achen MG, Stacker SA.

Ann N Y Acad Sci. 2008;1131:225-34. doi: 10.1196/annals.1413.020. Review.

PMID:
18519975
20.

The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.

Vandercappellen J, Liekens S, Bronckaers A, Noppen S, Ronsse I, Dillen C, Belleri M, Mitola S, Proost P, Presta M, Struyf S, Van Damme J.

Mol Cancer Res. 2010 Mar;8(3):322-34. doi: 10.1158/1541-7786.MCR-09-0176. Epub 2010 Mar 9.

Supplemental Content

Support Center